<DOC>
	<DOCNO>NCT00642603</DOCNO>
	<brief_summary>This 2-arm study design evaluate efficacy safety 2 treatment regimen Xeloda Avastin , either irinotecan oxaliplatin administer first 12 cycle , first line treatment patient metastatic colorectal cancer . Patients randomized receive 2-weekly cycle treatment either : 1 ) Xeloda , Avastin oxaliplatin ; 2 ) Xeloda , Avastin irinotecan . After 9 cycle , patient continue receive maintenance treatment Xeloda + Avastin . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Combination With Avastin + Short Course Chemotherapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient , ≥18 year age Histologically confirm adenocarcinoma colon rectum , unresectable metastatic locally advanced disease ≥1 measurable target lesion Ambulatory , Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Prior systemic therapy advance metastatic disease History another malignancy within last 5 year , except cure basal cell cancer skin cure cancer situ cervix Clinically significant cardiovascular disease Current recent use full dose oral warfarin full dose parenteral anticoagulant thrombolytic agent Chronic daily treatment &gt; 325 mg/day aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>